Vnitr Lek 2013, 59(3):201-203

Diabetic nephropathy/diabetic kidney disease

P. Bouček
Centrum diabetologie IKEM Praha, přednostka prof. MUDr. Terezie Pelikánová, DrSc.

Diabetic kidney disease (DKD), which belongs to the triad of diabetic microvascular complications, is currently the main cause of end-stage renal disease in developed countries. DKD usually simultaneously leads to a deteriorated long-term control of glucose metabolism and blood pressure, and to the development of diabetic retinopathy, neuropathy and atherosclerotic complications, which are the main causes of patients' mortality. Screening of the initial stages of DKD is to be based on the detection of increased albumin leak into the urine, microalbuminuria, and the reduction of renal function by means of estimates of glomerular filtration rate based on the serum creatinine level. The main objective of the prophylactic and treatment measures is to prevent the onset of DKD, or at least to stop its transition into an irreversible, progressive stage characterised by a permanent, often nephrotic proteinuria. The basic procedures in the prevention and treatment of DKD are maintaining the optimal metabolic control of diabetes and intensive hypertension treatment based on the inhibition of the renin-angiotensin system. Reaching the stage of progressive renal insufficiency (serum creatinine level approximately ≥ 200μmol/l) is an indication for further follow-up in the nephrology department, which will then take the necessary preparatory measures for dialysis treatment. The optimal method of kidney function replacement for patients with DKD is kidney transplantation, or combined kidney-pancreas transplantation in patients with type 1 diabetes.

Keywords: diabetic kidney disease; microalbuminuria; glomerular filtration; proteinuria; chronic kidney failure; kidney transplantation; combined kidney-pancreas transplantation

Received: February 4, 2013; Published: March 1, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Bouček P. Diabetic nephropathy/diabetic kidney disease. Vnitr Lek. 2013;59(3):201-203.
Download citation

References

  1. Péče o nemocné cukrovkou 2010. Praha: ÚZIS ČR; 2011.
  2. Hovind P, Tarnow I, Rossing K et al. Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes. Diabetes Care 2003; 26: 1258-1264. Go to original source... Go to PubMed...
  3. Girach A, Vignati L. Diabetic microvascular complications - can the presence of one predict the development of another? J Diab Compl 2006; 20: 228-237. Go to original source... Go to PubMed...
  4. Statistická ročenka dialyzační léčby v České republice v roce 2010. Česká nefrologická společnost; 2010; Available from: http://www.nefrol.cz/resources/upload/data/274_Rocenka2010.pdf.
  5. Mogensen CE, Christensen CK, Vittinqhus E. The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy. Diabetes 1983; 32: (Suppl. 2): 64-78. Go to original source... Go to PubMed...
  6. Doporučené postupy při diabetickém onemocnění ledvin. Česká diabetologická společnost ČLS JEP a Česká nefrologická společnost; 2012; Available from: http://www.diab.cz/dokumenty/standard_ledviny_12.pdf.
  7. Levey AS, Bosch JP, Lewis JB et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 1999; 130: 461-470. Go to original source... Go to PubMed...
  8. Mann JF, Schmieder RE, McQueen M et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372: 547-553. Go to original source... Go to PubMed...
  9. Parving HH, Brenner BM, McMurray JJV et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367: 2204-2213. Go to original source... Go to PubMed...
  10. Bouček P. Diabetická nefropatie - průvodce ošetřujícího lékaře. Praha: Maxdorf; 2011.




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.